IFRX
InflaRx N.V.
1.32
USD
This page is just a preview of the data found in TrendSpider’s full version
InflaRx N.V. stock is down -5.71% since 30 days ago. The next earnings date is Mar 20, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 57.14% of the previous 6 December’s closed higher than November.
InflaRx N.V. discovers and develops inhibitors using C5a technology. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases.
